Skip to main content

Table 3 Efficacy of different subgroup in CG

From: Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

 

C(n = 29)

AC(n = 31)

IC(n = 16)

AIC(n = 15)

ORR

20.7%

38.7%

25%

53.3%

PFS(m,95% CI)

3.4(2.3–4.5)

5.1(3.5–6.6)

5.5(2.7–8.2)

6.4(5.7–7.1)

  1. CG Chemotherapy group, C Chemotherapy alone subgroup, AC Anti-angiogenesis plus chemotherapy subgroup, IC Immune checkpoint inhibitors plus chemotherapy subgroup, AIC A combination of immune checkpoint inhibitors, anti-angiogenesis and chemotherapy subgroup, ORR Objective response rate, PFS Progression-free survival, CI Confidence interval
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us